Less than 5% of adults with thyroid eye disease who completed a full course of teprotumumab therapy required an additional course of the agent, according to a presenter at the American Thyroid Association annual meeting.
“We know from previous studies that the rate of recurrence with thyroid eye disease is anywhere between 15% and 20%,” Shoaib Ugradar, MD, oculoplastic surgeon at The Jules Stein Eye Institute at the University of California, Los Angeles, told Healio. “What this research shows us is that, of patients who receive teprotumumab therapy, only 4.9% of them went on